PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.27
D/E ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.14. Howard Marks would check for debt covenant compliance and refinancing risks.
0.66
Exceptionally low net debt at less than half the Drug Manufacturers - Specialty & Generic median of 1.87. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.
0.44
Coverage of 0.44 versus zero Drug Manufacturers - Specialty & Generic median interest expense. Walter Schloss would verify if our leverage provides advantages.
5.98
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.39. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
43.47%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.00%. Michael Burry would check for aggressive accounting and hidden risks.